

# VIENNA SEPTEMBER 9 - 13, 2023 eanm23.eanm.org



#### **Special Track Session 5**

**Neuroimaging Committee** 

#### **Debate**

Monday, September 11, 08:00 - 09:30

**Session Title** 

What is the Best Tracer for Molecular Brain Tumour Imaging?

Moderators
Francesco Fraioli (London, UK)

Point of View: Conventional tracers: Is it all about amino acid tracers or is there still a role for FDG? Francesco Cicone (Catanzaro, Italy)

Point of View: Conventional tracers: Novel radiotracers: why do we need more than amino acid tracers?

Nathalie Albert (Munich, Germany)

## **Educational Objectives**

- 1. During the debate one of the speakers will be in favour of using conventional tracers in the assessment of brain tumours, whereas the opponent will highlight the role of novel PET ligands to provide the important information required by clinicians.
- 2. The role of conventional tracers including FDG and amino-acids will be discussed with their clinical value, strengths, advantages in different tumours, and potential drawbacks in others
- The importance of new PET ligands will be tackled by the second speaker who will
  emphasises how specific PET tracers can provide information on tumour perfusion,
  angiogenesis and neuroinflammation pathways for a more specific understanding of the
  hallmarks of tumours.

### **Summary**

The session will help understanding the basic of conventional and novel PET tracers in brain tumours, with a revision of main known literature and important information of when, how and if a tracer should be preferred instead of another.

## **Key Words**

PET tracers; Astrocytoma; Non-enhancing gliomas; Oligodendroglioma; Primary central nervous system lymphoma.